AbCellera reported Phase 2 results for a NK3R-targeting therapy in vasomotor symptoms, positioning its program to compete for share in the hot-flash treatment market. The company’s shares rose after AbCellera said its mid-stage readout exceeded Wall Street expectations, with the NK3R-focused strategy generating positive topline data in a trial designed around clinically meaningful endpoints for vasomotor symptoms. AbCellera’s update adds to a rapidly evolving landscape of women’s health therapies where efficacy signals and endpoint performance are being closely scrutinized by investors. —